Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, has entered into a licensing agreement with Laboratorios Saval S.A. for the exclusive rights to market and sell Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), in an additional five countries in South America. Laboratorios Saval S.A. will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in Bol...